Skip to main content
    V

    Veracyte Inc (VCYT)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $24.01
    -0.32 (-1.32%)

    Market Cap: $1.96B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Veracyte Inc (VCYT) Financials: Revenue, Profit and Cash Flow

    Updated Nov 4, 2026. Financial statements from company filings, amounts in US dollars.

    Veracyte reported revenue of $517.14M for the fiscal year ended Dec 31, 2025, up 16.0% from the year before. That year, net income was $66.35M with a net margin of 12.8%, operating cash flow was $136.31M and free cash flow was $126.63M. The quarter ended Sep 30, 2026 had revenue of $151.75M and net income of $31.50M.

    Revenue and Margins

    The operating margin was 11.2% in the fiscal year ended Dec 2025, the highest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $65.08M, a compound annual rate of 25.9%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$517.14M+16.0%70.1%11.2%12.8%
    Dec 2024$445.76M+23.5%66.9%3.6%5.4%
    Dec 2023$361.05M+21.8%63.6%-23.8%-20.6%
    Dec 2022$296.54M+35.1%59.2%-13.9%-12.3%
    Dec 2021$219.51M+86.8%66.1%-37.3%-34.4%
    Dec 2020$117.48M-2.4%64.7%-30.1%-29.7%
    Dec 2019$120.37M+30.8%69.7%-12.6%-10.5%
    Dec 2018$92.01M+27.9%64.0%-24.2%-25.0%
    Dec 2017$71.95M+10.6%60.8%-36.9%-43.1%
    Dec 2016$65.08MN/A60.9%-44.3%-48.2%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income rose 174.9% from the year before. In the quarter ended Sep 2026, net income rose 64.6% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$517.14M$445.76M$361.05M$296.54M$219.51M$117.48M$120.37M$92.01M$71.95M$65.08M
    Cost of revenue$154.61M$147.62M$131.37M$120.86M$74.40M$41.45M$36.52M$33.08M$28.20M$25.46M
    Gross profit$362.53M$298.14M$229.68M$175.68M$145.11M$76.03M$83.84M$58.93M$43.76M$39.62M
    Research and development$70.81M$69.29M$57.30M$40.60M$29.84M$17.20M$14.85M$14.82M$13.88M$15.32M
    Operating income$57.78M$16.14M-$85.80M-$41.08M-$81.90M-$35.39M-$15.13M-$22.23M-$26.54M-$28.80M
    Net income$66.35M$24.14M-$74.40M-$36.56M-$75.56M-$34.91M-$12.60M-$23.00M-$31.00M-$31.36M
    EBITDA$86.35M$48.85M-$49.89M-$10.50M-$62.06M-$26.96M-$8.40M-$17.08M-$22.23M-$26.07M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$151.75M$150.32M$139.07M$140.64M$131.87M$130.16M$114.47M$118.63M$115.86M$114.43M$96.84M$98.20M
    Gross profit$107.10M$108.55M$101.16M$101.97M$91.28M$89.77M$79.51M$78.75M$79.01M$77.91M$62.47M$59.98M
    Operating income$16.57M$22.98M$22.65M$37.20M$22.95M-$5.27M$2.90M$4.17M$12.02M$4.61M-$4.66M-$35.51M
    Net income$31.50M$25.49M$28.71M$41.15M$19.14M-$980.00K$7.05M$5.11M$15.15M$5.73M-$1.86M-$28.29M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $1.33M by $361.25M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$1.41B$1.30B$1.11B$1.16B$1.19B$457.16M$275.21M$120.64M$78.67M$101.03M
    Current assets$488.38M$372.27M$285.62M$248.64M$243.10M$375.68M$187.69M$96.95M$53.93M$73.63M
    Cash and equivalents$362.58M$239.09M$216.45M$154.25M$173.20M$349.36M$159.32M$78.00M$33.89M$59.22M
    Total liabilities$96.44M$124.07M$70.80M$81.22M$91.31M$35.93M$35.76M$40.88M$41.44M$41.45M
    Short-term debt$1.33M$16.98M$2.66M$6.06M$3.81M$0$1.41M$1.36M$0$25.52M
    Long-term debtN/AN/AN/AN/AN/A$810.00K$694.00K$23.93M$24.94M$24.92M
    Shareholder equity$1.31B$1.18B$1.04B$1.08B$1.10B$421.23M$239.46M$79.75M$37.23M$59.58M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$1.57B$1.49B$1.44B$1.41B$1.37B$1.34B$1.32B$1.30B$1.28B$1.23B$1.20B$1.11B
    Total liabilities$139.99M$97.96M$91.99M$96.44M$110.12M$123.05M$120.47M$124.07M$98.98M$101.80M$81.42M$70.80M
    Cash and equivalents$199.83M$299.52M$263.14M$362.58M$315.57M$219.50M$186.12M$239.09M$274.08M$235.91M$209.19M$216.45M
    Shareholder equity$1.43B$1.39B$1.34B$1.31B$1.26B$1.22B$1.19B$1.18B$1.18B$1.13B$1.12B$1.04B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 92.9% of operating cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$136.31M$75.10M$44.22M$7.54M-$31.62M-$9.71M-$3.23M-$13.52M-$23.91M-$27.98M
    Capital expenditures$9.68M$11.29M$9.96M$8.55M$5.38M$2.84M$2.76M$1.87M$1.75M$4.21M
    Free cash flow$126.63M$63.81M$34.26M-$1.01M-$37.00M-$12.55M-$5.99M-$15.39M-$25.67M-$32.19M
    Dividends paidN/AN/AN/A$3.17MN/A$3.85M$977.00KN/A$0$0
    Investing cash flow-$9.21M-$56.27M$15.11M-$29.39M-$739.21M-$3.84M-$42.73M-$1.87M-$1.31M-$4.21M
    Financing cash flow-$4.22M$4.90M$2.84M$3.49M$596.32M$203.59M$127.29M$59.50M-$218.00K$52.33M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$40.26M$45.83M$35.22M$52.58M$44.76M$33.60M$5.36M$24.52M$29.96M$29.57M-$8.97M$15.55M
    Capital expenditures$2.33M$2.86M$2.96M$3.78M$2.79M$1.29M$1.82M$4.14M$2.24M$2.77M$2.13M$2.50M
    Free cash flow$37.92M$42.97M$32.25M$48.80M$41.97M$32.32M$3.54M$20.38M$27.72M$26.80M-$11.10M$13.05M
    Last 12 quarters

    Frequently Asked Questions About VCYT

    What is Veracyte's annual revenue?

    Veracyte reported revenue of $517.14M for the fiscal year ended Dec 31, 2025.

    How fast is Veracyte's revenue growing?

    Revenue was up 16.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 20.4%.

    Is Veracyte profitable?

    Yes. Veracyte reported net income of $66.35M for the fiscal year ended Dec 31, 2025, with a net margin of 12.8%.

    How much free cash flow does VCYT generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $136.31M minus capital expenditures of $9.68M produced free cash flow of $126.63M.

    How much debt does Veracyte have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $1.33M and cash and equivalents of $362.58M.